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SodiumAldosterone, a mineralocorticoid hormone mainly synthesized in the adrenal cortex, has been recognized to
be a regulator of cell mechanics. Recent data from a number of laboratories implicate that, besides kidney,
the cardiovascular system is an important target for aldosterone. In the endothelium, it promotes the
expression of epithelial sodium channels (ENaC) and modiﬁes the morphology of cells in terms of
mechanical stiffness, surface area and volume. Additionally, it renders the cells highly sensitive to small
changes in extracellular sodium and potassium. In this context, the time course of aldosterone action is
pivotal. In the fast (seconds to minutes), non-genomic signalling pathway vascular endothelial cells respond
to aldosterone with transient swelling, softening and insertion of ENaC in the apical plasma membrane. In
parallel, nitric oxide (NO) is released from the cells. In the long-term (hours), aldosterone has opposite
effects: The mechanical stiffness increases, the cells shrink and NO production decreases. This leads to the
conclusion that both the physiology and pathophysiology of aldosterone action in the vascular endothelium
are closely related. Aldosterone, at concentrations in the physiological range and over limited time periods
can stabilize blood pressure and regulate tissue perfusion while chronically high concentrations of this
hormone over extended time periods impair sodium homeostasis promoting endothelial dysfunction and the
development of tissue ﬁbrosis.Robert-Koch-Str. 27b, 48149
51 8355331.
-Vihrog).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Aldosterone, a steroid which affects the kidney and the
blood vessels
Aldosterone, a mineralocorticoid hormone mainly synthesized in
the zona glomerulosa of the suprarenal glands, plays a pivotal role in
the control of body ﬂuids and blood pressure. Its concentration in the
plasma of healthy humans varies over a wide range, between 0.05 and
0.5 nM. A major stimulus for its secretion is a decrease in extracellular
ﬂuid and/or a fall in blood pressure that triggers a cascade of enzyme
activation steps, which, within seconds, lead to the release of the
hormone from the suprarenal glands into the blood. The classical
targets for this hormone are the principal cells of the renal collecting
duct [1] in which aldosterone binds to intracellular mineralocorticoid
receptors which enhances NaCl reabsorption. In a close interaction
with other mechanisms (e.g., renal retention of water by the
antidiuretic hormone), NaCl and water are retained and the blood
pressure returns to normal.
It is worth looking at ‘time scales and quantities’ in order to
evaluate the efﬁciency of renal aldosterone action in the control of
blood pressure. Though chemically a steroid, the hormone is able to
trigger fast responses in kidney cells [2–4]. Aldosterone elicits a
number of cellular responses in seconds to minutes that ﬁnally leadto increased sodium chloride transport. As a rather conservative
estimate, aldosterone-triggered salt retention in the renal collecting
ducts starts about 30 min after the hormone is released from the
suprarenal glands and continues as long as plasma aldosterone
concentration remains raised. It is unlikely, however, that such a
mechanism retains a signiﬁcant amount of ‘ﬂuid volume’ within a
reasonably short time. For example, if all the NaCl in food is
retained, then, with an average salt consumption of 8–12 g/day, the
kidneys can only retain about 1 l of isotonic ﬂuid in 24 h (150 mM
NaCl=about 9 g/l) to increase blood pressure by volume expan-
sion. If the adult human body is composed of about 20 l of
extracellular ﬂuid, i.e., the compartment where the retained salt
and water will remain initially, then we must conclude that
aldosterone cannot restore the blood pressure to normal within
minutes or hours but only within days.
There is accumulating evidence that aldosterone acts on target
cells of the cardiovascular system [5–9], particularly, the vascular
endothelium [10,11]. Endothelial cells express mineralocorticoid
receptors and functionally respond to the hormone [12–14]. In vitro,
a prolonged exposure to aldosterone changes their morphology
considerably and cells derived from different tissues grow in size
and mechanically stiffen [11,15–17].
It has become increasingly evident that the mechanical stiffness
of a cell is fundamental for it to function properly. Stiffness is
important for cell motility, division, tissue organization, and cellular
responses to biochemical and biophysical signals [18]. It is altered in
Fig. 1. Cell volume and cell stiffness, obtained in human endothelial cells after acute
exposure to aldosterone. The transient volume increase is paralleled by a transient
decrease in cell stiffness. While cell volume normalizes after someminutes, cell stiffness
rises and remains increased as long as aldosterone is present (mean data of 10
measurements with 7–10 cells each are given). Cells were incubated in 100 nM
aldosterone, 1 µM spironolactone (modiﬁed after [27]).
Fig. 2. Cell water and solid cell mass expressed in percent of total cell volume of
individual human umbilical venous endothelial cells. Human endothelial cells were
grown for 3 days either in the absence (control) or presence of 1 nM aldosterone
alone and aldosterone (1 nM)+spironolactone (10 nM) (aldo+spiro). Please note
that the sum of cell water and the solid cell mass amounts to total cell volume
(modiﬁed after [23]).
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reduced [19] but it is increased in chondrocytes in arthritis [20],
airway smooth muscle cells in bronchial asthma [21] and ischemic
cardiac muscle [22]. Endothelial cells have a vulnerability to
mechanical shear forces that is likely to be increased when cells
stiffen [23]. Furthermore, in terms of endothelial cell stiffness,
aldosterone sensitizes the vascular endothelial cells to changes in
plasma sodium [24] while it renders them rather insensitive to
changes in plasma potassium [25].
2. Short-term action of aldosterone on the endothelium
A regulatory cell volume decrease after the acute application of
aldosterone has been identiﬁed in vascular endothelium [26,27].
Interestingly, it has been shown that the aldosterone-triggered
acute cell volume change is paralleled by a mirror-like change in
cell stiffness (Fig. 1). In the initial phase of the hormone response
(within 20 min), the cells swell and soften but after reaching a
maximum, cell volume returns to the original volume while the
cells stiffen. On returning to a steady state (aldosterone still
present!), the change in cell volume is inconspicuous while the
increase in cell stiffness persists. The increased stiffness indicates
that mechanical forces are involved in mechanisms of cell shrinkage
to its original volume. In parallel, cells contract [27]. The
physiological response of a contracted endothelial cell to certain
stimuli is likely to be abnormal. Vascular endothelium exposed to a
raised concentration of aldosterone decreases its synthesis and
release of nitric oxide [9,28,29]. This will have a major impact upon
blood vessel function for NO is a key regulator of vascular tone.
Since aldosterone stiffens endothelial cells it is probable that it is
this increased stiffness which reduces NO release. This assumption
is based upon the evidence that a pulsating ﬂow of blood exerts
shear forces at the endothelial cell wall, and the proposal that when
such a cell becomes stiffer it will be more difﬁcult to deform and
thus reduce its synthesis and release of NO [30].
3. Long-term action of aldosterone on the endothelium
One of the initial responses of an endothelial cell to aldosterone is
an increase in size [26]. It is probable that this increase is due to an
increased uptake of salt and water mediated by a rise in apically
expressed endothelial sodium channels [12]. This suggestion is
strongly supported by the inhibitory action of amiloride, a sodium
channel blocker used in mechanical measurements at single cell level.
It is interesting that some recent observations indicate that such
increases in cell volume may not be accompanied by an increase in
cell pressure. Estrogens, another class of steroid hormones, swell
endothelial cells even more than aldosterone but, at the same
substantially decreases cell stiffness [17]. Such ﬁndings question
whether aldosterone does indeed change thewater content of a target
cell rather than its solid mass.
This question was addressed bymeasuring cell water and solid cell
mass at single cell level [23]. Atomic force microscopy is the most
suitable method for such an approach, for several reasons: (i) Any
structures with heights in the range of up to 12 µm, adherent to a solid
surface, can be imaged at three dimensions and volumes quantiﬁed.
(ii) Images can be obtained in ﬂuid and in air. (iii) Fixed cells can be
used so that the organic contents of a cell remain in place while water
can be removed if desired. (iv) Surface coating that may inﬂuence the
quantitative data is not necessary.
Surprisingly, aldosterone did not increase cell water. On the
contrary, after 3 days there was a substantial increase in solid cell
mass and a diminution of cell water (Fig. 2). It is possible that the
sequence of events, triggered by aldosterone, is as follows: Upon
application of the hormone there is a fast non-genomic response.
This may comprise an inﬂux of inorganic ions across the plasmamembrane [2,31,32]. It is possible that even at this early stage of
mineralocorticoid action, classical intracellular receptors may be
involved [33]. The endothelial cell swelling observed as early as
5 min after application of the steroid, can be completely prevented
by the aldosterone receptor blocker spironolactone [26]. The fact
that the epithelial sodium channel blocker amiloride is also able to
prevent swelling strongly indicates that sodium inﬂux is closely
related to the volume increase. As mentioned above, some 20 min
later the volume of the endothelial cells decreases to normal [26].
Studies in oocytes suggest that within this ﬁrst 20 min of
aldosterone exposure the cell's genome is already activated,
which leads to export extrusion of mRNA from the cell nucleus
[34]. This suggests that the whole process of de novo protein
synthesis has been launched. It is not surprising therefore, that,
when aldosterone exposure is maintained over many days, the cells
grow in size (Fig. 3). It emphasizes aldosterone’s proliferative
character. Furthermore, endothelium exposed to aldosterone shows
‘gap formation’ between cells. In the light of a recent study showing
that aldosterone does not signiﬁcantly change paracellular perme-
ability [14], it is likely that such cells, surrounded by ‘gaps’ have
entered apoptosis which can be blocked by spironolactone [35].
Fig. 3. Images (top views) of human umbilical venous endothelial cells obtained with atomic force microscopy. Experiments were performed in primary cultures over a period of
2 weeks. The third dimension (cell height) is color-coded (see vertical color bar at bottom). 10 nM aldosterone swells the cells (see red-framed images) but diuretics (100 nM
mineralocorticoid antagonist spironolactone, coincubated with aldosterone or 1 µM plasmamembrane sodium channel blocker amiloride, added 60min prior to imaging) prevent it.
Please, note intercellular gaps (bottom image) during aldosterone exposure. Numbers below the respective images represent single cell volumes in femtoliter. Asterisks (*) indicate
signiﬁcant differences (pb0.05) between aldosterone-treated endothelium and the other mean values at a given time of incubation (modiﬁed after [16]).
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sodium channels
Aldosterone enters the cell, binds to the cytosolic mineralocor-
ticoid receptor (MR) and translocates into the nucleus where it
triggers a signal cascade and induces the transcription of a large
repertoire of aldosterone-responsive genes and a de novo synthesis
of proteins, such as ROMK, Na+/K+-ATPase and ENaC [36–38]. As a
result, sodium is retained and potassium is excreted by the
nephron. In addition to this classical response to aldosterone it
has become increasingly apparent that besides this slow (hours)
genomic signalling pathway, a fast non-genomic pathway does alsoexist which is characterized by an early onset (sec to min) [2,3,39]
and an insensitivity to transcription inhibitors [40]. Aldosterone
seems to regulate ENaC via both fast and slow pathways [41]. More
than 10 years ago, ENaC was identiﬁed and cloned from epithelial
tissues by Canessa et al. [42]. Up to now four different subunits have
been identiﬁed (α, β, γ and δ) and it was shown that they are
expressed in a tissue speciﬁc manner [43–45]. The membrane
insertion and activation of the sodium channel are complex and
described in a number of excellent review articles [46–48].
Although, ENaC was for a long time considered to be limited to
the kidney, colon and lung it is now known that vascular
endothelial cells also express ENaC, in addition to mineralocorticoid
Fig. 4. Human endothelial cells were maintained for 72 h in aldosterone-containing
medium. The paired experiment shows individual cells before amiloride application
(left image) and 5 min after amiloride exposure (right image). Cells shrink in volume
and decrease in apical surface by about 45% when 1 µM amiloride is added. (modiﬁed
after [50]).
Fig. 5. With semi-quantitative RT-PCR, the relative expression levels of α-ENaC mRNA
isolated from human endothelial cells (HUVEC) were detected. Control=HUVEC
incubated with solvent; Aldo=HUVEC incubated with 10 nM aldosterone for 72 h;
Aldo+Spiro=co-incubation with 10 nM aldosterone and 100 nM spironolatone for
72 h. Aldosterone signiﬁcantly increased (*) the transcription of α-ENaC compared to
control conditions while spironolactone prevented this effect (n=3).
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function [24,25]. It could be shown that the expression of ENaC in
endothelial tissues is regulated by aldosterone [14,50].
4.1. Short-term effects of aldosterone on ENaC expression
Aldosterone activation of ENaC usually takes some hours to
develop and can be blocked by inhibitors of transcription. There is
increasing evidence that aldosterone additionally may have acute
effects on ENaC expression. Such rapid effects have been described
in kidney and colon [51–53]. Furthermore, it was demonstrated that
in principal cells of the renal cortical collecting duct aldosterone
modiﬁes the rapid surface expression and insertion of ENaC via a
protein kinase D dependent mechanism [54]. In this context, a
membrane receptor was detected which could mediate the
aldosterone effects and enables the rapid insertion of ENaC
molecules into the plasma membrane [55]. To explore the ‘time
scale’ of aldosterone regulatory pathways in endothelia, short-term
experiments were performed on live endothelial cells. Using an
AFM, it was found that within 10 min aldosterone increases
endothelial cell volume by approximately 20%. Since this effect
can be prevented by the highly speciﬁc ENaC blocker amiloride and
the mineralocorticoid receptor antagonist spironolactone, it was
concluded that this rapid response to aldosterone is mediated by
ENaC [26]. Furthermore, it was tested whether the aldosterone-
induced sodium inﬂux rapidly modiﬁes the biomechanical proper-
ties of the cells. Human endothelium was treated with physiological
concentrations of aldosterone to stimulate ENaC expression and
membrane insertion. Interestingly, within 5 min the application of
amiloride decreased the surface area by almost 45% (Fig. 4) [50].
This intriguing ﬁnding supported other experiments where a fast
amiloride-induced cell shrinkage in aldosterone-pretreated cells
was detected [11]. It is possible that the reduction of the
intracellular sodium concentration, due to the functional blockade
of ENaC, induces a signalling cascade which initiates the degrada-
tion of the channel.
It is suggested that aldosterone inserts, as a non-genomic short-
term response, preformed ENaCmolecules into the plasmamembrane
of endothelial cells which activate sodium and water inﬂux into the
cell. As a result, the volume and surface of the cells transiently
increase.
4.2. Long-term effects of aldosterone on ENaC expression
As described above, aldosterone induces sustained changes in
the morphology of endothelial cells. Since this can be blocked by
amiloride, it can be suggested that the endothelial ENaC is involved
in this cellular event. With semi-quantitative RT-PCR, we have
demonstrated that the mRNA expression level of ENaC in human
endothelial cells is regulated by aldosterone. Incubation in 1 nM
aldosterone increases the α-ENaC subunit mRNA in human
endothelial cells by approximately 22%, while co-incubation with
100 nM spironolactone, a mineralocorticoid receptor antagonist,
completely prevents this effect (Fig. 5). This indicates that
aldosterone activates the transcription of ENaC via the (slow)
genomic pathway thereby effectively increasing the total amount of
proteins in the cell. By using the Western blot technique, it could be
conﬁrmed that long-term incubation with aldosterone increases the
total ENaC protein amount by approximately 50%, which also can be
reduced by spironolactone [14]. This, as discussed above, may
contribute to the rise in cell mass.
Accordingly, in immunoﬂuorescence experiments, aldosterone
stimulates the insertion of ENaC molecules into the apical
membrane by approximately 30% within 72 h, spironolactone
again can prevent the effect (Fig. 6) [50]. Taken together, these
ﬁndings demonstrate that long-term aldosterone treatment ofendothelial cells leads to an augmented synthesis and membrane
abundance of ENaC molecules. It has been described that the C-
terminus of the α-ENaC subunit interacts with F-actin in the
submembraneous cytoskeleton [56,57] which seems to be impor-
tant for the proper function of endothelial cells [12]. By increasing
the number of ENaC molecules in the plasma membrane, the
interaction with proteins of the cortical cytoskeleton could be
strengthened leading to an increased mechanical stiffness of the
cells.
5. Sodium modiﬁes the properties of endothelial cells
As described above the highly speciﬁc and functional ENaC
blocker, amiloride has the ability to prevent cell swelling [26] and
surface area increase [50] and to reduce the stiffness of endothelial
cells [23]. This suggests that the sodium inﬂux into the cell is a key
player in these events. Recently, it was shown that plasma sodium
concentrations above 140 mM (physiological concentration) stiffen
endothelial cells and reduce the release of NO [24]. Since NO is the
major regulator of blood vessel tone, this inverse correlation
between stiffness and NO release may be important both physio-
logically and medically. It implies that the concentration of plasma
sodium determines endothelial cell elasticity, and that the vascular
Fig. 6. The relative surface expression of ENaCmolecules was detected with speciﬁc anti
α-ENaC antibodies. Control=HUVEC incubated with solvent; Aldo=HUVEC incubated
with 10 nM aldosterone for 72 h; Aldo+Spiro=co-incubation with 10 nM aldosterone
and 100 nM spironolatone for 72 h; Aldo+Amiloride=aldosterone-pretreated cells
were incubatedwith 1 µM amiloride for 1 h. Mean values of 10 cells per group are given.
The asterisk indicates the signiﬁcance difference in comparison with control (pb0.01).
(modiﬁed after [50]).
Table 1
Short-term effects of aldosterone on endothelial NO release.
[Aldosterone] in
medium or
infusion
In vivo/in
vitro/in
situ
NO
bioavailability,
↑ / ↓ / ↔
Method Ref.
3.3–55 pM In vivo ↑ FBF [94]
0.01 nM–1.0 µM In vitro ↑ Fluorescent probe [70,76]
5–10 nM In vitro ↑ NO selective
electrode,
ﬂuorescent probe
Fels et al.
(unpublished)
≤1 nM In situ ↑ Diameter of
arterioles
[82]
18 nMpl In vivo ↑ FBF [71]
0.01–100 nM In situ ↑ Diameter/
constriction of
arteries
[69]
0.1–10 nM In situ ↓ Diameter/
constriction of
arteries
[64,95]
2.5 pM/min In vivo ↓ FBF [96]
1.3–3.3 nMpl In vivo ↓ FBF [97]
5.3–20.5 nM In vivo ↓ Systemic vascular
resistance
[98]
28–277 nmol/
min
In vivo ↔ FBF [99]
1.4 µmol
injection
In vivo ↔ Renal plasma ﬂow [100]
Conditions of aldosterone treatment andeffects onendothelialNOrelease are summarized
(↑=increase, ↓=decrease,↔=nochange detected, n.m.=notmeasured, FBF=forearm
blood ﬂow).
Table 2
Long-term effects of aldosterone on endothelial NO release.
[Aldosterone]
in medium
or infusion
In vivo/in
vitro/in situ
NO release,
↑ / ↓ / ↔
Method Ref.
788 nM/d
ﬂudrocortisone
In vivo ↑ FBF [94]
0.45 nM In vitro ↓ Nitrite concentration [24,25]
100 nM In vitro ↓ cGMP measurement [29]
Only endogenous In vivo,
hypertensive
rats
↓ eNOS protein level, eNOS
phosphorylation, nitrite
concentration
[81]
2 µmol/h In situ, rat
mesenteric
arteries
↓ Vessel relaxation studies [77]
2 µmol/h In vivo ↓ Systolic blood pressure
analysis
[78]
Only endogenous In vivo ↓ FMD [28]
12 pmol/min/kg In vivo ↓ FBF [80]
n.m. In vivo ↓ FBF [79]
Conditions of aldosterone treatment andeffects onendothelialNOrelease are summarized
(↑=increase, ↓=decrease,↔=nochange detected, n.m.=notmeasured, FBF=forearm
blood ﬂow, FMD=ﬂow mediated dilation).
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changes in blood vessel function [24]. It appears therefore that
sodium per se might be a major regulator of these cellular events
and possess similar characteristics to those of aldosterone. Exces-
sive salt consumption leads to the development of hypertension
and cardiovascular disease [58] and a high salt intake increases local
aldosterone production in cardiovascular tissue [59]. Therefore,
high extracellular sodium could lead to the following sequence of
events: Due to an increase of extracellular sodium, aldosterone is
locally produced in endothelial tissues and stimulates the fast
membrane insertion of ENaC molecules which, after some delay,
increase the stiffness of the cells. If aldosterone is raised over a
prolonged time, the stiff endothelial cells release less nitric oxide,
which is perhaps one of the abnormalities which cause progressive
vascular dysfunction.
6. Regulation of nitric oxide release by aldosterone
The signaling molecule NO is a gaseous radical with a relative short
half life of less than 5 s and a very short diffusion distance of ∼300 µm
[60,61]. It is themajor regulator of the vascular smoothmuscle tone. NO
is synthesized in the vascular system by the endothelial nitric oxide
synthase (eNOS). In addition, two other isoforms of the nitric oxide
synthase (NOS) are known, neuronal and inducible NOS (nNOS, iNOS),
which in the healthy organism play a minor role in the regulation of
endothelial function. Upon synthesis in the endothelium, NO diffuses
the short distance to the adjacent vascular smoothmuscle cells. There it
activates soluble guanylylcyclase (sGC), which, via cGMP, phosphor-
ylates themyosin light chain kinase and Ca2+-ATPase, thereby inducing
vasodilation. Additionally, to its function in blood pressure control NO
also plays a role in other signaling pathways.
The regulation of eNOS is rather complex and the exact mechan-
isms are not yet completely understood [62,63]. In the vascular
system, aldosterone is an important regulator of NO bioavailability.
Since it acts via a fast (min) non-genomic pathway, as well as via a
slow (hours) genomic pathway, the changes in cellular function it
induces can be observed at different time scales. Some of these
responses are listed in Tables 1 and 2.
6.1. Short-term effects of aldosterone on nitric oxide release
The acute effects of aldosterone on NO release are controversial
(see Tables 1 and 2). In the literature, experiments can be foundwhich
indicate a short-term increase in NO bioavailability whereas other
experiments apparently show the opposite. One of the sources of thisdiscrepancy may be the variable deﬁnition of ‘short-term’ and ‘long-
term’. In some publications, a pre-incubation of aldosterone for more
than 1 h is still entitled ‘short-term’ or ‘acute’whereas others consider
seconds and minutes as ‘acute.’ For the sake of clarity, only
aldosterone-induced effects over periods of up to 30 min will be
referred to as ‘short-term.’ Other experiment with in which
aldosterone application times are longer than 30 min will be regarded
as ‘long-term.’ Nevertheless some controversies remain as indicated
in Tables 1 and 2.
Publications report that acute aldosterone treatment inhibits
endothelial NO release. Aldosterone induces a calcium-dependent
vasoconstriction via the activation of protein kinase C (PKC)
[64,65]. This effect can be mimicked by the application of the
eNOS blocker N-Nitro-L-arginine- methyl ester (L-NAME) which
indicates that aldosterone inhibits eNOS activity at an early stage.
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ticoid receptor (MR) must be the mediator of this response by
reason that the aldosterone receptor antagonist eplerenone
inhibits the negative effect of acute aldosterone treatment, [65].
Furthermore, endothelial Na+ transport seems to be involved in
aldosterone-dependent acute eNOS inhibition. Application of high
concentrations of amiloride (100 µM) which block Na+ transport
via, e.g., both the Na+/H+ exchanger 1 (NHE1) and ENaC inhibits
the aldosterone-induced decrease of NO bioavailability [65].
However, these ﬁndings do not necessarily lead to the conclusion
that aldosterone acutely inhibits endothelial NO production
because rather high concentrations of sodium were used in this
study [65]. Since it has been shown that chronic aldosterone
treatment, together with high sodium concentrations, leads to
reduced NO release in endothelial cells [24], it cannot be excluded
that high sodium concentrations per se have induced this effect
[66–68]. Additionally, it cannot be excluded that the vasoconstric-
tive effect of aldosterone could be independent of endothelial cells.
It is likely that this effect is caused directly by an inﬂuence of
aldosterone on vascular smooth muscle cells (VSMC). This view is
supported by the fact that arterioles lacking the endothelium show
an increased aldosterone-induced contraction compared to intact
arterioles [64,69,70]. In addition, it has been shown that the co-
infusion of aldosterone and L-NAME induces an increased vaso-
constriction, as compared to an infusion with aldosterone alone
[71]. Thus, it may be concluded that aldosterone-induced vaso-
constriction detected either in situ or in vivo is not correlated with
an acute inhibition of eNOS but explained by a direct aldosterone-
induced contraction of smooth muscle.
This hypothesis may also explain why others reported that
aldosterone induces an acute transient increase of NO bioavailability
in endothelial cells. It has been shown in the afferent arterioles of
renal glomeruli that the acute application of very low concentrations
of aldosterone decreases the efﬁciency with which K+ induces
vasoconstriction [72,73]. Very low aldosterone concentration may
act speciﬁcally only on the endothelial cell layer while vascular
smooth muscle cells remain unaffected. It is tempting to suggest that
the negative effects of aldosterone are only induced when aldosterone
concentrations are high.
The assumption that aldosterone-triggered NO release occurs is
supported by data from recent in vitro experiments. Fluorescent
indicators allow the detection of NO release at single cell level.
Diamonoﬂuoresceine and its derivates (e.g., DAF-2 DA, DAF-FM DA)
are commonly used for intracellular NO ﬂuorescent imaging [74,75].
Acute addition of aldosterone leads to a transient increase of
intracellular DAF-2 ﬂuorescence intensity in primary bovine aortic
endothelium [70]. Interestingly, this study revealed a dose-dependent
aldosterone effect. Additionally, Mutho et al. showed that in primary
bovine endothelial cells aldosterone increases eNOS phosphorylation
[76]. They also showed that aldosterone-inﬂuenced NO release and
that a short-term incubation of aldosterone increased eNOS phos-
phorylation and NO release, whereas this effect was not detected
during a long-term application of aldosterone. The transient nature of
NO production may be due to an acute increase in endothelial calcium
for endothelial cells acutely respond to aldosterone with increasing
intracellular Ca2+ [31,66]. Since eNOS is activated by Ca2+/calmod-
ulin, the released Ca2+ may potentiate eNOS activity.
We have studied the acute and chronic effects of aldosterone on
the release of NO from endothelial cells. NO selective electrodes and
ﬂuorescent NO indicators were used to analyze the acute effect of
aldosterone. In addition, the long-term effect of aldosterone on NO
release was examined via the Griess assay. As shown in Fig. 7, an
acute application of aldosterone on bovine aortic endothelial cells
(GM7373) induces a transient release of NO within 20 min, whereas
prolonged treatment with aldosterone decreases NO bioavailability
(Fig. 8).6.2. Long-term effects of aldosterone on nitric oxide release
In general, prolonged exposure of endothelial cells to aldosterone
decreases NO bioavailability. Although a direct measurement of NO in
long-term experiments is difﬁcult (because of the short half-life of
NO), there are several methods available which can detect NO
metabolites, or stable NO substrates (e.g., nitrite, nitrate or sGC/
cGMP). Therefore, the long-term effects of aldosterone are well
documented.
As shown in Fig. 8, in vitro studies reveal that a prolonged exposure
to aldosterone decreases nitrite concentration in the medium [25].
The concentration of cellular cGMP is reduced in parallel [29]. In
addition, it has been shown that chronic aldosterone treatment
induces a decreased ability of rat mesenteric arteries to contract [77].
In each of these three studies, aldosterone receptor antagonists
(spironolactone, eplerenone) abolished the aldosterone-effect, which
indicates that the mineralocorticoid receptor mediates the aldoste-
rone-induced long-term decrease in NO bioavailability. This conclu-
sion is supported by in vivo experiments analyzing rat arterial blood
pressure [78], human forearm blood ﬂow [28] and ﬂow mediated
dilatation, after prolonged exposure to aldosterone [79,80]. Although
the speciﬁc mechanisms underlying the chronic (and pathological)
aldosterone effects are still unknown, it is quite clear that aldosterone
induces a decrease in eNOS expression, eNOS phosphorylation and
nitrite production [81].
6.3. Acute aldosterone-induced NO release: a hypothesis
The described ﬁndings lead to a new hypothesis to explain acute
aldosterone-induced NO release from endothelial cells. Controversial
results obtained from different laboratories had led to a dilemma
which was probably due to three facts: (i) An inconsistent deﬁnition
of the terms ‘acute’ and ‘chronic.’ Therefore, it is important to have a
close look at ‘time scales’ and results obtained by acute aldosterone
administration should be separated from those obtained with long-
term aldosterone incubation. (ii) The different aldosterone and salt
concentrations used in the various studies can cause conﬂicting
effects. High concentrations of aldosterone and/or salt may have
different effects than low concentrations. Therefore, it is necessary, to
take the right ‘quantities’ into account. (iii) The effects of aldosterone
itself on vascular smooth muscle cells. Since endothelial cells are also
targets for aldosterone, their potential response should not be
neglected in both in situ and in vivo studies.
In our postulated model in endothelial cells, aldosterone inhibits
NO release during long-term application whereas an acute exposure
induces NO production. This short-term NO release is of transient
nature with a bell-shaped dose-dependency [70,82].
This view is also supported by studies demonstrating a correlation
between NO and the mechanical stiffness of the cells [24,25,83,84].
Namely, aldosterone induces a transient softening of the cells and as a
result a fast and transient NO production which is reversed within
minutes (Fig. 1).
The limited amount of NO produced, due to transient eNOS activity
during the early response to aldosterone may not be sufﬁcient to
induce smooth muscle relaxation but, instead, it may inﬂuence other
signaling pathways in the endothelial cells. It is known that, besides
its function as a vasodilator, NO acts as a messenger molecule. Thus,
NO can inﬂuence other signal cascades by modifying, e.g., kinases and
G protein-coupled receptors [85–87]. In this context, it has been
shown that shear stress-induced NO release leads to an s-nitrosylation
of several proteins including ER-ATPase, HSP90, and tubulin beta
chain [88]. So far, we are not aware of any study concerning
aldosterone-induced protein modiﬁcation by s-nitrosylation. It has
already been shown that the two eNOS pools, one underneath the
plasmamembrane and the other in the Golgi-apparatus, are regulated
separately [87,89]. Therefore, it is suggested that Golgi-linked eNOS
Fig. 7. Short-term effect of aldosterone on endothelial NO release of bovine aortic endothelial cells GM7373 was recorded by ﬂuorescence microscopy or amperometric NO
measurement. (A) Cells were loaded with the intracellular NO indicator DAF-2 DA (Merck, Darmstadt, Germany). Due to the covalent binding of NO to the ﬂuorescent indicator, the
slope of the measured ﬂuorescence intensity was calculated and analyzed as relative NO release. (B) NO release into the culture medium was detected with the NO selective
electrodes (ISONOP007,WPI, Serasota, USA). Upon application of aldosterone, a rapid and transient increase of NO synthesis was detected. Ionomycin was used as a gold standard for
quantiﬁcation during the amperometric NO detection (Fels et al., unpublished).
Fig. 8. Acute and chronic effects of aldosterone on NO release by bovine aortic
endothelial cells are shown. Short-term effects were analyzed with NO selective
electrodes (ISONOP007, WPI, Serasota, USA) (n=5) and the ﬂuorescent NO indicator
DAF-2 DA (Merck, Darmstadt, Germany) (n=40). Nitrite assays were used to
document effects of aldosterone in a period of 24 h (n=16). Each experiment was
signiﬁcantly different to the respective control (*p≤0.05) (modiﬁed after [25], Fels et
al., unpublished).
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membrane. This suggestion is also supported by several other
publications, which investigated eNOS activity at the Golgi-apparatus
and the plasma membrane [90–93].
7. Conclusions
The mineralocorticoid hormone aldosterone is a critical regula-
tor of the biomechanical properties of endothelial cells, and its
action is mediated by endothelial ENaC. The mechanisms involved
are either ‘fast’ (minutes) or ‘slow’ (hours). The latter occurs when
the hormone is released after a stimulus from the adrenal cortex
and acts ‘systemically.’ Both endothelial and vascular smooth
muscle cells are targeted by aldosterone, resulting in blood vessel
constriction.
Nevertheless, what are the physiological mechanisms responsible
for the short-term effects? A low concentration of aldosterone
stimulates the release of NO within minutes paralleled by a transient
softening of endothelial cells. Such ‘local’ transient aldosterone-
induced NO release should relax smooth muscle but this tends to be
opposed by the direct constrictive effect of ‘systemic’ aldosterone on
Fig. 9. Left side: Local endogenous aldosterone production stimulates the release of NO
which acts directly on the smooth muscle cells. This leads to transient short-term
vasodilation. Right side: Systemic aldosterone reduces the NO release leading to long-
term vasoconstriction.
1200 J. Fels et al. / Biochimica et Biophysica Acta 1802 (2010) 1193–1202vascular smooth muscle (Fig. 9). Thus, the net result (constriction or
dilation) appears to be predominantly dependent upon both
systemically and locally released aldosterone. The subject needs
further investigation.Acknowledgements
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